Alzheimer’s Benefits May Continue After Donanemab Treatment Ends, Data Suggest

(MedPage Today) — New data suggested that donanemab (Kisunla) sustained long-term benefits after a limited dosing period in a subgroup of people with early symptomatic Alzheimer’s disease.
Early Alzheimer’s patients who completed their course…